BRAF G596R

CI-VAR-00001767Explore in graph →NP_004324.2:p.Gly596ArgNM_004333.4:c.1786G>CClinVar 375943 CIViC 1627 rs121913361

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm2
BRAF G596R	Cetuximab	Predictive	D	Supports Sensitivity Response	3	submitted	EID12443 Several BRAF mutant cell lines were analyzed in response to treatment with increasing concentrations of cetuximab (0-300nM). Cell-growth and impact on signalling was measured: ERK signalling by wester… (full text at CIViC) PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF G596R	Vemurafenib	Predictive	D	Does Not Support Sensitivity Response	1	accepted	EID4729 In an in vitro study, an NCI-H508 cell line expressing BRAF G596R demonstrated insensitivity to vemurafenib treatment compared to HT29 cells expressing BRAF V600E (a known vemurafenib sensitizing muta… (full text at CIViC) PMID 22180495 · Yang et al., 2012 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
BRAF G596R	Vemurafenib	Predictive	C	Does Not Support Sensitivity Response	2	accepted	EID5969 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. Of 26 patien… (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic

Solid Neoplasm1
BRAF G596R	Vemurafenib	Predictive	D	Does Not Support Sensitivity Response	3	submitted	EID7558 RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R). PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic